Key result
This editorial discusses the potential of 18F-fluorodeoxyglucose PET/CT imaging to predict radiofrequency catheter ablation success in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
This editorial discusses the potential role of 18F-FDG PET/CT imaging in predicting the success of radiofrequency catheter ablation in patients with atrial fibrillation.
This editorial refers to ‘18F-fluorodeoxyglucose PET/CT imaging in atrial fibrillation: a pilot prospective study’, by B. Xie et al. doi: 10.1093/ehjci/jeab088. Atrial fibrillation (AF) is the most common arrhythmia in daily practice.1 Many AF patients remain symptomatic despite optimal medical therapy, including rate-control or rhythm-control drugs.1 Refractory symptomatology is the primary indication for catheter ablation, which can be performed effectively with various energy sources, and which has been shown to improve quality of life.1,2 Pulmonary vein isolation is the primary technique, and it is performed with the express intent of restoring sinus rhythm.1 Data are also emerging that catheter ablation may improve outcome: a reduction in the combined endpoint of mortality and heart failure hospitalization was seen in the Catheter Ablation versus Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE-AF) trial.3
No takes yet. Share an insight, caveat, or question.
Bijl et al. (2021) conducted an editorial in Atrial fibrillation. This editorial discusses the potential of 18F-fluorodeoxyglucose PET/CT imaging to predict radiofrequency catheter ablation success in patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: